Literature DB >> 7693342

Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized.

O Tounekti1, G Pron, J Belehradek, L M Mir.   

Abstract

Bleomycin (BLM), a compound currently used in anticancer therapy, is unable to cross the plasma membrane efficiently. Electropermeabilization allows a defined number of BLM molecules to enter directly into the cell cytoplasm. Such a procedure has revealed that BLM is intrinsicly highly cytotoxic. Here we show that the mechanisms of the cell death caused by BLM are closely related to the number of BLM molecules introduced into the cell cytoplasm. When only a few thousand BLM molecules are internalized, cells display an arrest in the G2-M phase of the cell cycle and become enlarged and polynucleated before dying. These observations parallel the "mitotic death" seen with ionizing radiations. By contrast, when several million molecules of BLM are internalized, morphological changes identical to those usually associated with apoptosis are observed as well as very rapid DNA fragmentation into oligonucleosomal-sized fragments. We demonstrate that this fragmentation, which occurs within a few seconds after BLM internalization, is consistent with the direct internucleosomal cleavage of chromatin by BLM. Our findings reinforce the importance of DNA digestion as an early and essential step in the morphological changes associated with apoptosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693342

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  58 in total

1.  DNA damage-induced mitotic catastrophe is mediated by the Chk1-dependent mitotic exit DNA damage checkpoint.

Authors:  Xingxu Huang; Thanh Tran; Lingna Zhang; Rashieda Hatcher; Pumin Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-13       Impact factor: 11.205

2.  Image-guided local delivery strategies enhance therapeutic nanoparticle uptake in solid tumors.

Authors:  Samdeep K Mouli; Patrick Tyler; Joseph L McDevitt; Aaron C Eifler; Yang Guo; Jodi Nicolai; Robert J Lewandowski; Weiguo Li; Daniel Procissi; Robert K Ryu; Y Andrew Wang; Riad Salem; Andrew C Larson; Reed A Omary
Journal:  ACS Nano       Date:  2013-08-20       Impact factor: 15.881

Review 3.  Nucleic acids electrotransfer-based gene therapy (electrogenetherapy): past, current, and future.

Authors:  L M Mir
Journal:  Mol Biotechnol       Date:  2009-06-27       Impact factor: 2.695

4.  Some repair-deficient mutants of Dictyostelium discoideum display enhanced susceptibilities to bleomycin.

Authors:  R A Deering; R B Guyer; L Stevens; T E Watson-Thais
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

5.  Electroporation of DC-3F cells is a dual process.

Authors:  Lars H Wegner; Wolfgang Frey; Aude Silve
Journal:  Biophys J       Date:  2015-04-07       Impact factor: 4.033

6.  Dependence of Electroporation Detection Threshold on Cell Radius: An Explanation to Observations Non Compatible with Schwan's Equation Model.

Authors:  Borja Mercadal; P Thomas Vernier; Antoni Ivorra
Journal:  J Membr Biol       Date:  2016-05-11       Impact factor: 1.843

7.  Electrodelivery of drugs into cancer cells in the presence of poloxamer 188.

Authors:  Iana Tsoneva; Iordan Iordanov; Annette J Berger; Toma Tomov; Biliana Nikolova; Nikola Mudrov; Martin R Berger
Journal:  J Biomed Biotechnol       Date:  2010-07-25

8.  Mass Transfer Model for Drug Delivery in Tissue Cells with Reversible Electroporation.

Authors:  Yair Granot; Boris Rubinsky
Journal:  Int J Heat Mass Transf       Date:  2008-11       Impact factor: 5.584

9.  Treatment of cancer with cryochemotherapy.

Authors:  L M Mir; B Rubinsky
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

Review 10.  Adjuvant electrochemotherapy in veterinary patients: a model for the planning of future therapies in humans.

Authors:  Enrico P Spugnini; Gennaro Citro; Alfonso Baldi
Journal:  J Exp Clin Cancer Res       Date:  2009-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.